Novo Nordisk Is a Screaming Buy, AlphaValue Says -- Market Talk

Dow Jones

04-02

1125 GMT - Novo Nordisk is a "screaming buy," AlphaValue analyst Abhishek Raval writes. The company has a lead in the obesity market, a solid pipeline, aggressive intent toward licensing deals, and a valuation lower than both Novartis and AstraZeneca, he says. Underwhelming late-stage results from obesity candidate CagriSema, Trump tariff uncertainty, and concerns around a guidance downgrade due to competitive pressures have all weighed on Novo's share price. Nonetheless, AlphaValue has already baked some caution into 2025 estimates and still expects Novo's bottom line to register a 16% compound annual growth rate, which would be the highest among European big pharma over 2024-2027. AlphaValue lowers its target price on the stock to 943 Danish kroner from 981 kroner and retains its buy rating. Shares fall 2.4% to 467.75 kroner. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

April 02, 2025 07:25 ET (11:25 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2524461832"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524461832\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2524461832?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-02 19:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524461832","market":"hk","top_or_hot":-1,"title":"Novo Nordisk Is a Screaming Buy, AlphaValue Says -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1125 GMT - Novo Nordisk is a \"screaming buy,\" AlphaValue analyst Abhishek Raval writes. The company has a lead in the obesity market, a solid pipeline, aggressive intent toward licensing deals, and a valuation lower than both Novartis and AstraZeneca, he says. Underwhelming late-stage results from obesity candidate CagriSema, Trump tariff uncertainty, and concerns around a guidance downgrade due to competitive pressures have all weighed on Novo's share price. Nonetheless, AlphaValue has already baked some caution into 2025 estimates and still expects Novo's bottom line to register a 16% compound annual growth rate, which would be the highest among European big pharma over 2024-2027. AlphaValue lowers its target price on the stock to 943 Danish kroner from 981 kroner and retains its buy rating. Shares fall 2.4% to 467.75 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 02, 2025 07:25 ET (11:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Is a Screaming Buy, AlphaValue Says -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Is a Screaming Buy, AlphaValue Says -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-04-02 19:25</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1125 GMT - Novo Nordisk is a \"screaming buy,\" AlphaValue analyst Abhishek Raval writes. The company has a lead in the obesity market, a solid pipeline, aggressive intent toward licensing deals, and a valuation lower than both Novartis and AstraZeneca, he says. Underwhelming late-stage results from obesity candidate CagriSema, Trump tariff uncertainty, and concerns around a guidance downgrade due to competitive pressures have all weighed on Novo's share price. Nonetheless, AlphaValue has already baked some caution into 2025 estimates and still expects Novo's bottom line to register a 16% compound annual growth rate, which would be the highest among European big pharma over 2024-2027. AlphaValue lowers its target price on the stock to 943 Danish kroner from 981 kroner and retains its buy rating. Shares fall 2.4% to 467.75 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 02, 2025 07:25 ET (11:25 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2524461832","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524461832","pubTimestamp":1743593100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1125 GMT - Novo Nordisk is a \"screaming buy,\" AlphaValue analyst Abhishek Raval writes. The company has a lead in the obesity market, a solid pipeline, aggressive intent toward licensing deals, and a valuation lower than both Novartis and AstraZeneca, he says. Underwhelming late-stage results from obesity candidate CagriSema, Trump tariff uncertainty, and concerns around a guidance downgrade due to competitive pressures have all weighed on Novo's share price. Nonetheless, AlphaValue has already baked some caution into 2025 estimates and still expects Novo's bottom line to register a 16% compound annual growth rate, which would be the highest among European big pharma over 2024-2027. AlphaValue lowers its target price on the stock to 943 Danish kroner from 981 kroner and retains its buy rating. Shares fall 2.4% to 467.75 kroner. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"AlphaValue表示，诺和诺德值得大力买入——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"1125 GMT - Novo Nordisk is a \"screaming buy,\" AlphaValue analyst Abhishek Raval writes. The company has a lead in the obesity market, a solid pipeline, aggressive intent toward licensing deals, and a valuation lower than both Novartis and AstraZeneca, he says. Underwhelming late-stage results from obesity candidate CagriSema, Trump tariff uncertainty, and concerns around a guidance downgrade due to competitive pressures have all weighed on Novo's share price. Nonetheless, AlphaValue has already baked some caution into 2025 estimates and still expects Novo's bottom line to register a 16% compound annual growth rate, which would be the highest among European big pharma over 2024-2027. AlphaValue lowers its target price on the stock to 943 Danish kroner from 981 kroner and retains its buy rating. Shares fall 2.4% to 467.75 kroner. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2025 07:25 ET (11:25 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}